International Stereotactic Radiosurgery Society

Become a member | Log In | Contact us

The ISRS webinar series began in 2016. We have already delivered over 50 webinars on intracranial and body SRS and from experts around around the world.

A video replay of each past webinar is available to ISRS members.

Next Webinars

February 27, 2019

SRS in Spinal AVMs by Kita SALLABANDA

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 10:00 am (Brasilia) - 10:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 11:00 pm (Brisbane)

Spinal Arteriovenous Malformations (AVMs) are rare but very important with high morbidity pathology, especially when localized intra-medullary. We have to transfer all our knowledge about the treatment of brain AVMs in different conditions, and different organs at risk. For these reasons, it is very important to have all the necessary information including angiography, MRI, and to clarify which type of intra-medullary AVMs we can treat.  There are four types of medullary AVMs but only type II can be treated.

Is very important the adequate technology and the margin dose have to be decided in relationship with the localization, volume and blood supply. 

In this webinar, we will present some cases and plan the philosophy of treatment.

March 07, 2019

The Origins and Development of Radiosurgery and the Leksell Gamma Knife by Dan LEKSELL

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 10:00 am (Brasilia) - 10:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 11:00pm (Brisbane)

In the 1930’s a young Lars Leksell joined Herbert Olivecrona in his operating room in Stockholm. The experience, with all its “blood, sweat and tears” and with up to 60 percent surgical mortality, prompted a lifelong quest for ways to minimize neurosurgical trauma. In the late 1940’s he developed his own stereotactic instrument, the basic principle of which became the basis for the methodology that in a landmark paper of 1951 was termed radiosurgery. The first tool for radiosurgery, the Leksell Gamma Knife, was finalized in 1967. Since then radiosurgery has evolved to cover much of what neurosurgeons do every day and over 1.2 million patients have benefited from non-invasive Gamma Knife brain surgery worldwide.

April 10, 2019

Boron Neutron Capture Therapy: current state and future perspectives by Alexander ZABORONOK

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)

Boron neutron capture therapy (BNCT) is a unique alternative approach to malignant tumor radiotherapy that provides eradication power at the single tumor cell level within normal tissues holding curative potential for invasive cancers, including head and neck cancer, malignant melanoma, and multiform glioblastoma.

May 23, 2019

Stereotactic radiotherapy for oligometastatic cancer: expanding reality by Barbara Alicja JERECZEK-FOSSA

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)

The incidence of oligometastatic cancer (low burden metastatic disease) is constantly growing due to the advancement in medical imaging and increase in primary cancer cure rates. Metastasectomy and other local modalities including stereotactic radiotherapy, termoablation, high intensity focus ultrasound (HIFU) etc. have been introduced in this particular clinical scenario. New terms like metastasis-directed therapy (MDT) and local or lesion ablative treatment (LAT) have been coined and help to distinguish the radical local strategies from palliative local therapies (palliative treatment). Stereotactic radiotherapy is now frequently proposed in oligometastatic cancer patient and provides high local control and, in some cases, long lasting progression-free and treatment-free intervals. 

July 11, 2019

When is SABR the Preferred Treatment in Lung Cancer? by Ben SLOTMAN

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00 pm (Brisbane)

The clinical use of SABR for early stage non-small cell lung cancer has increased considerable during the last decade. In this webinar, current and future indication for SABR in this disease will be discussed. Treatment of patients with a higher risk of toxicity due to tumor location or presence of interstitial lung disease will be addressed as well.